SMXXF Stock UPDATES Summit Corporation (SMXXF) 2.3000 09/09/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Summit Corporation (SMXXF) 2.3000 $SMXXF

Plague - Pipeline Review, H1 2014
M2 - Wed Jul 30, 2:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xgdb3j/plague_pipeline) has announced the addition of the "Plague - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Plague, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plague and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Plague - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Plague and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Takeda Pharmaceutical - Summit Corporation - Mucosis - iBio - Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/xg...e_pipeline

Dementia Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pmw68m/dementia) has announced the addition of the "Dementia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dementia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Sylentis S.A. - FORUM Pharmaceuticals Inc. - Ildong Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - WhanIn Pharmaceutical Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Summit Corporation plc - Oryzon Genomics S.A. - Intellect Neurosciences, Inc. - Intra-Cellular Therapies, Inc. - Tautatis Incorporated - Pacific Northwest Biotechnology, LLC - Otsuka Holdings Co., Ltd. - Chase Pharmaceuticals Corporation - Echo Pharmaceuticals B.V. - Chronos Therapeutics Limited - Alector LLC - ImStar Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/pmw68m/dementia

USHCC Announces 2014 Legislative Summit Featured Speakers
GlobeNewswire - Mon Mar 24, 9:07PM CDT
The United States Hispanic Chamber of Commerce (USHCC) is proud to announce the participation of an all-star lineup during its 2014 Legislative Summit, which will take place at the Capital Hilton from March 25 - 27. The Legislative Summit is the USHCC's premier advocacy event where the Hispanic business community hears from national political leaders, have access to high-level networking opportunities, engage in policy workshops, participate in procurement matchmaking sessions with federal agencies, and have the chance to meet with Congressional representatives on Capitol Hill.

Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Plague - Latest Pipeline Review Report
M2 - Mon Jan 27, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/9r77ph/plague_pipeline) has announced the addition of the "Plague - Pipeline Review, H2 2013" report to their offering. 'Plague - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Plague, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Plague. Scope - A snapshot of the global therapeutic scenario for Plague. - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Plague pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Plague - Companies Involved in Therapeutics Development - Takeda Pharmaceutical Company Limited - Summit Corporation plc - Mucosis B.V. - iBio, Inc. - Cellceutix Corporation Drug Profiles - rF1V Vaccine - Flagellin/F1/V Vaccine - PMX-30016 - SMT-15000 - Subunit Vaccine For Plague - Plague Vaccine - Yersinia Pestis Vaccine - Subunit Vaccine For Anthrax-Plague Combination - Yersinia Pestis Vaccine - Yersinia Pestis Vaccine - tPA-V DNA Vaccine - Small Molecule to Inhibit YoPH for Plague For more information visit http://www.researchandmarkets.com/research/9r...e_pipeline

Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Tuberculosis - Pipeline Review, H2 2013 Reviews Key Players Involved in the Therapeutic Development for Tuberculosis
M2 - Mon Sep 02, 11:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bnt58v/tuberculosis) has announced the addition of the "Tuberculosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Tuberculosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tuberculosis, complete with latest updates, and special features on late-stage and discontinued projects. Tuberculosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Tuberculosis. - A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Tuberculosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - AVI BioPharma Inc. - Achillion Pharmaceuticals, Inc. - Advinus Therapeutics Pvt. Ltd. - Archivel Farma S.L. - AstraZeneca PLC - B&C Biopharm - BT PHARMA - Canopus BioPharma Incorporated - Chimerix, Inc. - Crucell N.V. - Eli Lilly and Company - Ensoltek Co., Ltd. - EpiVax, Inc. - GlaxoSmithKline Inc. - GlaxoSmithKline plc - Hollis-Eden Pharmaceuticals, Inc. - ISA Pharmaceuticals B.V. - Immune Network Research Ltd. - ImmunoBiology Limited - ImmunoVaccine Technologies Inc. - Johnson & Johnson - Lipotek Pty Ltd - Medisyn Technologies, Inc. - MicuRx Pharmaceuticals, Inc. - Mondobiotech Holding AG - NeED Pharma s.r.l. - Okairos - Pharminox Limited - Piramal Healthcare Limited - Pt. Bio Farma - Recipharm AB - Sanofi-Aventis - Sequella, Inc. - Snowdon Inc. - Statens Serum Institut - Summit Corporation plc - TVAX Biomedical, LLC - Transgene SA - Vakzine Projekt Management GmbH - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. For more information visit http://www.researchandmarkets.com/research/bn...berculosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Ebola Viral Infections - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g94m3t/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola Viral Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola Viral Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola Viral Infections. Scope - A snapshot of the global therapeutic scenario for Ebola Viral Infections. - A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola Viral Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Tekmira Pharmaceuticals Corp. Medicago Inc. CombinatoRx, Incorporated Summit Corporation plc Functional Genetics, Inc. Evolva SA Vaxart, Inc. Prosetta Corporation For more information visit http://www.researchandmarkets.com/research/g9...bola_viral About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Metastatic Melanoma - Pipeline Review, H2 2012
M2 - Mon Aug 12, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mttj8/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H2 2012" report to their offering. This data provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Melanoma. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Metastatic Melanoma - A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Coverage of products based on various stages of development ranging from discovery till registration stages - A feature on pipeline projects on the basis of monotherapy and combined therapeutics - Coverage of the Metastatic Melanoma pipeline on the basis of route of administration and molecule type - Key discontinued pipeline projects - Latest news and deals relating to the products Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Metastatic Melanoma Overview Therapeutics Development An Overview of Pipeline Products for Metastatic Melanoma Companies Involved in Metastatic Melanoma Therapeutics Development Metastatic Melanoma - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - 3SBio Inc - AVAX Technologies - Abbott Laboratories - Antigenics - BioAlliance Pharma - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics - Eli Lilly and Company - F. Hoffmann-La Roche - Genentech - GlaxoSmithKline - Hemispherx Biopharma - Incyte Corporation - Lorus Therapeutics - Millennium Pharmaceuticals - Molecular Insight Pharmaceuticals - Morphotek - Northwest Biotherapeutics - Novartis AG - Oncolytics Biotech - Ono Pharmaceutical - Osta Biotechnologies - Oxford BioMedica - Pain Therapeutics - Progen Pharmaceuticals Limited - Provectus Pharmaceuticals - Summit Corporation - Vical Incorporated - Viralytics For more information visit http://www.researchandmarkets.com/research/5mttj8/metastatic

Skin Inflammation - Pipeline Review, H2 2012
M2 - Wed Jul 31, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cclx3v/skin_inflammation) has announced the addition of the "Skin Inflammation - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the Skin Inflammation therapeutic pipeline. This report provides information on the therapeutic development for Skin Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Inflammation. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Skin Inflammation Overview Therapeutics Development An Overview of Pipeline Products for Skin Inflammation Companies Involved in Skin Inflammation Therapeutics Development Skin Inflammation - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Combination Products Assessment by Route of Administration Assessment by Molecule Type Drug Profiles Skin Inflammation Therapeutics - Drug Profile Updates Skin Inflammation Therapeutics - Discontinued Products Skin Inflammation Therapeutics - Dormant Products Skin Inflammation - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned - APEIRON Biologics AG - Action Pharma A/S - Almirall, S.A - Amgen Inc - AnGes MG, Inc - AnaMar Medical AB - Anacor Pharmaceuticals, Inc - Array BioPharma Inc - Asubio Pharmaceuticals, Inc - Bayer HealthCare AG - Bristol-Myers Squibb Company - CREABILIS Therapeutics S.r.l. - Celtic Pharmaceutical Holdings L.P - Clarassance, Inc - Companies Involved in Skin Inflammation Therapeutics Development - Cutanea Life Sciences - Daiichi Sankyo Company, Ltd - Deciphera Pharmaceuticals, LLC - EMS S.A - Eisai Co., Ltd - Fougera - Galderma S.A. - GlaxoSmithKline plc - Hanall Pharmaceutical Co., Ltd - Hawthorn Pharmaceuticals, Inc - Hygeia Therapeutics, Inc - IMMD Inc. - JADO Technologies GmbH. - LEO Pharma A/S - MIKA Pharma GmbH - Maruho Co.,Ltd - MedImmune LLC - Melior Discovery, Inc. - Morphotek, Inc - Morria Biopharmaceuticals Plc - NKT Therapeutics, Inc - NicOx SA - Nippon Shinyaku Co., Ltd - Novartis AG - Nuvo Research Inc. - Oxagen Limited - Palau Pharma S.A - Paloma Pharmaceuticals, Inc - Pharis Biotec GmbH - Phytopharm Plc - ProMetic Life Sciences Inc - Provectus Pharmaceuticals, Inc - Proximagen Neuroscience plc - R-Tech Ueno, Ltd - Regeneron Pharmaceuticals, Inc - Respiratorius AB - SARcode Corporation - SWITCH Biotech LLC - Stiefel Laboratories, Inc - Summit Corporation plc - Syntrix Biosystems, Inc - Viromed Co., Ltd - Welichem Biotech Inc For more information visit http://www.researchandmarkets.com/research/cc...flammation

Dermatitis - Pipeline Review, H2 2012
M2 - Fri Jul 26, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrd9dn/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dermatitis. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Dermatitis. - A review of the Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dermatitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Dermatitis Overview Therapeutics Development An Overview of Pipeline Products for Dermatitis Dermatitis Therapeutics under Development by Companies Dermatitis Therapeutics under Investigation by Universities/Institutes Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Early Clinical Stage Products Comparative Analysis Discovery and Pre-Clinical Stage Products Comparative Analysis Dermatitis Therapeutics - Products under Development by Companies Dermatitis Therapeutics - Products under Investigation by Universities/Institutes Companies Involved in Dermatitis Therapeutics Development Drug Profiles Dermatitis Therapeutics - Drug Profile Updates Dermatitis Therapeutics - Discontinued Products Dermatitis Therapeutics - Dormant Products Dermatitis - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned: (58) Including: - Almirall, S.A - Amgen Inc - AnGes MG - Array BioPharma Inc - Bayer HealthCare AG - Bristol-Myers Squibb Company - Daiichi Sankyo Company - Eisai Co - Galderma S.A - GlaxoSmithKline - Hanall Pharmaceutical Co - LEO Pharma A/S - MedImmune LLC - NicOx SA - Nippon Shinyaku Co - Novartis AG - Nuvo Research Inc - Phytopharm - ProMetic Life Sciences Inc - Provectus Pharmaceuticals - Proximagen Neuroscience - R-Tech Ueno - Regeneron Pharmaceuticals, Inc - Stiefel Laboratories - Summit Corporation For more information visit http://www.researchandmarkets.com/research/hrd9dn/dermatitis

Anthrax - Pipeline Review, H1 2013 Provides Coverage of the Anthrax Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Tue Jun 04, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ssbkc/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Anthrax - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anthrax, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anthrax. Anthrax - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Anthrax. - A review of the Anthrax products under development




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dimora's MegaSorb Review Sharpens Wound Care Choices

Updated Category News Views 105

Wound care is one of those corners of healthcare where flashy language runs into real-life consequences fast. Dimora Medical’s newly announced collaboration with podiatric physician Dr. Ebonie Vincent-Sleet brings a professional voice to its MegaSorb silicone foam dressing line, specifically a 4×4-inch product reviewed for its intended place in care. That is useful...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 80

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 174

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
Highway 99 Truck Death Puts Safety Records in Focus

Updated Category News Views 97

A stopped car on a highway shoulder is supposed to be a bad day, not a death sentence. Yet on November 5, 2026, a person helping a relative with a disabled vehicle was killed on northbound Highway 99 in Elk Grove after a commercial tractor-trailer allegedly drifted onto the shoulder, hit both stationary vehicles, and overturned. Northbound lanes were closed for hours. A...

Continue Reading
Cedar’s Fast 500 Spot Shows Billing Tech’s Momentum

Updated Category News Views 89

A 486th-place finish can look like the last seat on the bus, but Cedar’s 102% revenue growth from 2022 through 2025 is not nothing. Healthcare billing is a miserable, deeply entrenched corner of the economy where legacy systems have had decades to dig in. Growing at all while selling technology into health systems deserves a serious look, even if nobody should confuse a...

Continue Reading
A Quanzhou Table Offers China Beyond the Headlines

Updated Category News Views 7

Steam rising from a Quanzhou table can carry more weight than another polished speech about cultural exchange. That is the sensible instinct behind Home Banquets with Master Chefs, the CCTV-4 series using regional meals to explore geography, customs and memory. It is not trying to explain China through a pile of statistics or a museum-label summary. It starts where people...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 8

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 124

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Envision’s COP31 Pitch Hinges on Grid Execution, Not Targets

Updated Category News Views 24

A 2,500 GW traffic jam is a rotten place to park climate ambition. Envision Energy used COP31 in Antalya to make the more useful point: clean-power targets mean very little if grids cannot connect, balance and dispatch the electricity. Kane Xu’s message was not another round of flag-waving promises. It was an argument that the constraint has shifted from wanting...

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 131

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading

Top 5 Most Recently Viewed Articles

Edge Data Center Growth Driven by AI and Streaming Demand

Updated Category News Views 319

Edge Data Center Market Overview The edge data center market is projected to grow significantly, with an estimate of USD 22.11 billion growth from 2024 to 2028. This trend aligns with the increasing demand for video streaming services and the incorporation of artificial intelligence (AI) technologies into data center operations. With a compound annual growth rate (CAGR)...

Continue Reading
Four Attorneys Elevated to Director Roles at Goulston & Storrs

Updated Category News Views 209

Exciting Leadership Changes at Goulston & Storrs Goulston & Storrs, a distinguished Am Law 200 law firm based in Boston, is thrilled to announce the promotion of four exceptional attorneys to the role of Directors. This esteemed recognition reflects their dedication, expertise, and significant contributions to both the firm and its clients. Meet the New Directors Among...

Continue Reading
ODNB and NACB Merge: A Big Leap in Community Banking

Updated Category News Views 208

Merging Titans in Community Banking Folks, we've got a colossal merger happening in the cozy yet combative world of community banking—ODNB Financial Corporation is hitching wagons with National Capital Bancorp, Inc. Now, you'd be forgiven for not popping champagne over this unless your bread is buttered by $2.4 billion in assets and the shiny allure of becoming a big...

Continue Reading
Shell's Latest Prospectus Supplement Overview and Insights

Updated Category News Views 157

Shell International Finance B.V. and Shell plc Publish Prospectus Supplement Shell International Finance B.V. and Shell plc have recently made available significant financial documents for stakeholders and investors. This announcement revolves around the publication of their prospectus supplement. Available Financial Documents The following documents, hereafter referred...

Continue Reading
Jeff Lurie's Remarkable NFL Investment Journey and Success

Updated Category News Views 497

Jeff Lurie: From Professor to NFL Mogul Jeff Lurie, the proud owner of the Philadelphia Eagles, recently celebrated his second Super Bowl win, marking a significant milestone in a journey that began with a purchase of the franchise for $185 million back in 1994. Today, this team is valued at an astonishing 35 times that initial investment, showcasing Lurie’s sharp...

Continue Reading